First, we have to recognize that smoking in the lung cancer survivor is common, despite its affects on mortality and QOL. We must recognize that cancer survivors have specific characteristics that impact their ability to quit smoking. They have depressive symptoms, low quitting self efficacy, as well as a low perceived risk of smoking and benefit from quitting.14–15 We need to develop interventions specific to these characteristics. We think that the measures suggested by the American Society of Clinical Oncology16 and other professional societies need to be implemented. These include increased efforts to discourage tobacco use in the young, increasing the price of cigarettes by raising federal taxes, ensuring tobacco settlement funds are devoted to health-related projects, reforming third-party payment for tobacco cessation efforts, further restriction of second-hand smoke in public places, supporting research into tobacco addiction, and implementing a halt of US government promotion of tobacco products.16We do not believe that regulation of tobacco products17 to decrease the lethality of the product will work. We believe that all health-care professionals, including nurses, pharmacist, social workers, physicians, and respiratory therapists, etc.,1,18 should be involved in advising our cancer survivors about smoking cessation. Finally, we think that pulmonary physicians, oncologists, and other professionals involved in the care of cancer survivors should be working with a multidisciplinary group of professionals who should evaluate the cancer survivors during each visit to the physician to establish pharmacologic, behavioral, and other types of therapies that have been shown to be effective in tobacco use cessation. We don’t need to find new reasons to tell people that smoking is bad; we have enough.